Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11165149 | 0.89 | KDM4E (0.66) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL9468787 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL11346886 | 0.84 | KDM4E (0.78) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL9468711 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL3162634 | 0.80 | KDM4E (0.72) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL5804188 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL30579781 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL11161734 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL30579799 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 | |
| SCHEMBL9468197 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| EP-1885367-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | Wyeth (US) | 2008-02-13 | — | — | EP | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| US-20060270677-A1 | Method for the treatment of noise phobia in companion animals | WYETH (US) | 2006-11-30 | — | — | US | claimed |
| WO-2006127574-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | WYETH (US) | 2006-11-30 | — | — | WO | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| EP-0025819-B1 | SUBSTITUTED PYRAZOLO (1,5-A) PYRIMIDINES, AND THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-10-12 | — | — | EP | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| CN-101184492-A | Methods for treating noise phobia in companion animals | WYETH CORP (US) | 2008-05-21 | — | — | CN | disclosed |
| EP-1885367-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | Wyeth (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1885367-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | Wyeth (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060270677-A1 | Method for the treatment of noise phobia in companion animals | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0025819-B1 | SUBSTITUTED PYRAZOLO (1,5-A) PYRIMIDINES, AND THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-10-12 | — | — | EP | disclosed |
| US-4281000-A | Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents | AMERICAN CYANAMID COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| EP-0025819-A1 | Substituted pyrazolo (1,5-a) pyrimidines, and their preparation | AMERICAN CYANAMID COMPANY (US) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | KDM4E 3705/4885ALDH1A1 1128/4885HPGD 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.